Pristyn Research Solutions


Premium online & offline Pharmacovigilance training with 100% placement and internship.

What is mean by Pharmacovigilance ?

Pharmacovigilance (PV) is defined as the science and activities relating to the detection, assessment, understanding and prevention of adverse effects or any other drug-related problem. WHO established its Programme for International Drug Monitoring in response to the thalidomide disaster detected in 1961. Together with the WHO Collaborating Centre for International Drug Monitoring, Uppsala, WHO promotes PV at the country level. At the end of 2010, 134 countries were part of the WHO PV Programme. The aims of PV are to enhance patient care and patient safety in relation to the use of medicines; and to support public health programmes by providing reliable, balanced information for the effective assessment of the risk-benefit profile of medicines

Pharmacovigilance course provided by the Pristyn research solution to improve the skill of candidate through its training on fundamental principle of pharma and technical concepts which are used in pharmaceutical.

Duration of Course:
  • For three month Program: The recommended period of training is three month provide the internship letter and training certificate of Pharmacovigilance
    Contents of the training will be as per updated current companies’ requirements and as per international guidelines and regulations.
  • For six month Programs: The recommended period of training is six month provides the internship letter, post-graduation diploma course certificate and training course certificate of clinical research, in six month training, four month theoretical training and two month soft skill development including English and life skills communication and practical knowledge in company.
  • Program Highlight: The program highlighted with 24×7 learning management system, content is developed by expert of academics and industry, use of advance technology and faculty interaction, placement assistant, Maharashtra Medical Council accredited National seminar provides an opportunities of interaction with subject expert and networking with stakeholders.The entire certificate provided to candidates is government approved which makes the student to stand unique with corer of students.
Eligibility Criteria :
  • B.Pharm/Pharm/Pharm.D
  • B.SC/M.SC (botany, zoology, chemistry, biotechnology, biochemistry, microbiology, genetics, nursing).
  • All Life Science Graduates and Post Graduates
  • M.B.B.S/B.D.S/B.A.M.S/B.H.M.S /B.V.Sc/B.S.M.S Best for Fresher’s/Mid-term career change/Better career growth
Admission Procedure:
  • Register and pay registration fee offline or Online
  • Attached scan documents and get verified by our company
  • Pay online/offline program fee and print application form
  • Get study training material regularly from the joining date
Companies where candidate can join after Pharmacovigilance Course and training
Position in Pharmacovigilance
  • Drug Safety associate
  • Senior Medical Advisor
  • Safety Associate Trainee
  • Senior Executive
  • Pharmacovigilance Manager
  • Clinical Pharmacologist
Some common terms are used during pharmacovigilance Practice are follows :
  • Adverse event reporting
    1. Individual Case Safety Report (ICSR)
    2. Coding of adverse events
    3. Seriousness determination
    4. Expedited reporting
    5. Clinical trial reporting
    6. Spontaneous reporting
    7. Aggregate reporting
    8. Other reporting methods
Risk Management:
  1. Causality assessment
  2. Signal detection
  3. Risk management plans
  4. Risk/benefit profile of drugs
  5. Pharmacoepidemiology
  6. Pharmacogenetics and pharmacogenomics
 International collaboration:
  1. The World Health Organization (WHO)
  2. The International Council for Harmonisation (ICH)
  3. The Council for International Organizations of Medical Science (CIOMS)
  4. The International Society of Pharmacovigilance (ISoP)
 Regulatory Authorities:
  1. United States
  2. Emerging economies (including Latin America)
  3. European Union
  4. Rest of Europe, including non-EU
  5. Japan
  6. Canada